Clinical Trials Logo

Coronavirus Disease 2019 clinical trials

View clinical trials related to Coronavirus Disease 2019.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05330832 Active, not recruiting - Clinical trials for Coronavirus Disease 2019

Covid-19 Associated Coagulopathy Predicted by Thrombodynamic Markers (CoViTro-I)

Start date: April 1, 2020
Phase:
Study type: Observational

The aim of the study is estimating the predictive and preventative capability of thrombodynamics for severe pneumonia coagulopathy complications in patients with COVID-19 infection. Thrombodynamics test is a method for blood coagulation and anticoagulation monitoring. It could be a useful tool for predicting thrombohemorrhagic complications in patients with COVID-19 infection and developing a novel scheme of anticoagulant therapy. Inclusion criteria are the following: patient informed concern, confirmed COVID-19 diagnosis, state of modern or critical condition.

NCT ID: NCT05216471 Active, not recruiting - Clinical trials for Coronavirus Disease 2019

Identify Coronavirus Disease by Chest X-ray

Start date: May 1, 2021
Phase:
Study type: Observational

to identify the diagnostic accuracy of chest X-ray in diagnosis of Coronavirus disease19 .

NCT ID: NCT05128643 Active, not recruiting - Clinical trials for Coronavirus Disease 2019

Clinical Study on the Immune Program of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell)

Start date: September 17, 2021
Phase: Phase 3
Study type: Interventional

Popular topic:Clinical study on the immune program of recombinant Novel Coronavirus (COVID-19) vaccine (CHO cell). Research purpose:Main purpose: To evaluate the immunogenicity of recombinant novel coronavirus vaccine (CHO cells) inoculated at 0,1,6 months or 0,1,4 months in persons aged 18 years and over. Secondary purpose: To evaluate the safety of the investigational vaccine in people aged 18 and above. Overall design: In this study, recombinant novel coronavirus vaccine (CHO cells) is inoculated at 0,1,6 months or 0,1,4 months in persons aged 18 years and older to evaluate the immunogenicity and safety. Study population:The study involved people 18 years of age and older. Test groups:A total of 300 subjects were enrolled, including 221 in the 18-59 age group and 79 in the ≥60 age group. Three doses of experimental vaccine were administered according to the 0,1,6 month immunization schedule (Study No. 001-150) or 0,1,4 months immunization schedule (Study No. 151-300).

NCT ID: NCT05077332 Active, not recruiting - COVID-19 Clinical Trials

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

Start date: December 29, 2021
Phase: Phase 2
Study type: Interventional

This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.

NCT ID: NCT04347239 Active, not recruiting - Clinical trials for Coronavirus Disease 2019

Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Start date: April 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.